Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 91Carcinoma, Non-Small-Cell Lung 84Neoplasms 48Carcinoma, Renal Cell 44Neoplasm Metastasis 40Carcinoma, Hepatocellular 36Squamous Cell Carcinoma of Head and Neck 35Colorectal Neoplasms 31Pancreatic Neoplasms 24Lung Neoplasms 20Stomach Neoplasms 19Head and Neck Neoplasms 18Carcinoma, Transitional Cell 17Hodgkin Disease 16Breast Neoplasms 16Small Cell Lung Carcinoma 15Ovarian Neoplasms 14Urinary Bladder Neoplasms 13Recurrence 13Advanced Cancer 13Glioblastoma 12Brain Neoplasms 12Lymphoma 11Kidney Neoplasms 11Glioma 11Prostatic Neoplasms 10Lymphoma, Non-Hodgkin 10Uveal Melanoma 9Triple Negative Breast Neoplasms 9Sarcoma 9

Interventions

Gemcitabine 7Leucovorin 6Irinotecan 6Fluorouracil 6130-nm albumin-bound paclitaxel 6Albumin-Bound Paclitaxel 5napabucasin 4Capecitabine 4Paclitaxel 3Oxaliplatin 3Ocoxin 3Bevacizumab 3pembrolizumab 2entinostat 2Sorafenib 2Imatinib Mesylate 2Everolimus 2Cyclophosphamide 2Cisplatin 2Cetuximab 25,10-methylenetetrahydrofolic acid 2tislelizumab 1spartalizumab 1pralsetinib 1palbociclib 1irinotecan sucrosofate 1halofantrine 1guadecitabine 1fludarabine 1ficlatuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Digestive System Neoplasms × Nivolumab × Clear all
NCT04299880 2023-11-08

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Sumitomo Pharma America, Inc.

Phase 1 Completed
7 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡